The EPS miss and recent capital raises suggest cash burn is running ahead of expectations, but the strengthened balance sheet supports runway into H2 2027. Key catalyst is the Q4 2026 BLA submission; monitor for any updates on confirmatory study or FDA interactions.
Price Chart
Executive Summary
Spruce Biosciences reported Q1 2026 net loss of $12.3M ($(8.94)/share), missing consensus EPS of $(7.32) by 22%. Cash and equivalents stood at $54.1M as of March 31, 2026, with a preliminary $107.3M as of April 30 following a $69M underwritten public offering. The company continues to advance TA-ERT toward a planned BLA submission in Q4 2026.
Key Financial Metrics
Key Facts
- Q1 2026 net loss: $12.3M ($(8.94)/share) vs $14.0M ($(23.95)/share) in Q1 2025
- Cash and equivalents: $54.1M at March 31, 2026; $107.3M (preliminary) at April 30, 2026
- Closed $69M underwritten public offering on April 22, 2026
- TA-ERT BLA submission on track for Q4 2026; no FDA-approved therapy for MPS IIIB currently
Financial Impact
EPS miss of 22% vs consensus; net loss $2.3M worse than expected
Risk Factors
- EPS miss may pressure the stock near-term
- Dilution from recent offerings (1.15M shares + warrants)
- Regulatory risk: BLA submission and FDA approval uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-220648 |
| Document: sprb-20260513.htm | 0001193125-26-220648 |
| Document: 0001193125-26-220648-index-headers.html | 0001193125-26-220648 |
| Document: 0001193125-26-220648-index.html | 0001193125-26-220648 |
| Document: 0001193125-26-220648.txt | 0001193125-26-220648 |
| 8-K Data (Synthetic) | 0001193125-26-220648 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | 8-K | $47.07 $54.35 | ▲ +15.47% | ▲ +17.36% | $43.99 (−6.54%) |
May 13, 2026 23w ago | 8-K | $57.55 $49.11 | ▼ −14.67% | ▼ −14.06% | $43.99 (−23.56%) |
Apr 21, 2026 26w ago | 424B5 | $52.36 $48.25 | ▼ −7.85% | ▼ −11.01% | $43.99 (−15.99%) |
Apr 20, 2026 27w ago | 424B5 | $51.69 $51.41 | ▼ −0.54% | ▼ −5.46% | $43.99 (−14.90%) |
Mar 9, 2026 33w ago | 8-K | $62.11 $62.15 | ▲ +0.06% | ▲ +2.87% | $43.99 (−29.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers